| Status | Suspended |
| Process | STA |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Alice Law |
| Project manager: | Jeremy Powell |
| Technical Lead: | Ahmed Elsada |
Consultees
| Manufacturers/sponsors | AB Science (masitinib) |
| Others | Department of Health |
| NHS Leeds South and East CCG | |
| NHS England | |
| NHS Telford & Wrekin CCG | |
| Welsh Government | |
| Patient/carer groups | Afiya Trust |
| Beating Bowel Cancer | |
| Black Health Agency | |
| Bladder and Bowel Foundation | |
| Bowel Cancer Information (formerly Lynn’s Bowel Cancer Campaign) | |
| Bowel Cancer UK | |
| Cancer Black Care | |
| Cancer Equality | |
| Cancer52 | |
| Equalities National Council | |
| GIST Support UK | |
| Helen Rollason Cancer Charity | |
| Independent Cancer Patient’s Voice | |
| Macmillan Cancer Support | |
| Maggie’s Centres | |
| Marie Curie Cancer Care | |
| Muslim Council of Britain | |
| Muslim Health Network | |
| Ochre | |
| Oesophageal Patients Association | |
| Rarer Cancers Foundation | |
| Sarcoma UK | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Tenovus | |
| Professional groups | Association of Cancer Physicians |
| Association of Surgeons of Great Britain and Ireland | |
| Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland | |
| British Association for Services to the Elderly | |
| British Association of Surgical Oncology | |
| British Geriatric Society | |
| British Institute of Radiology | |
| British Psychosocial Oncology Society | |
| British Society of Gastroenterology | |
| Cancer Network Pharmacists Forum | |
| Cancer Research UK | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| Society and College of Radiographers | |
| UK Health Forum | |
| United Kingdom Clinical Pharmacy Association | |
| United Kingdom Oncology Nursing Society |
Commentators
| Associated Guideline Groups | National Collaborating Centre for Cancer |
| Associated Public Health Groups | Public Health England |
| Public Health Wales NHS Trust | |
| Comparator manufacturer(s) | Pfizer (sunitinib) |
| Evidence Review Group | Aberdeen HTA Group |
| National Institute for Health Research Health Technology Assessment Programme | |
| General | Allied Health Professionals Federation |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Commissioning Support Appraisals Service | |
| Department of Health,Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| NHS Alliance | |
| NHS Commercial Medicines Unit | |
| NHS Confederation | |
| Scottish Medicines Consortium | |
| Relevant research groups | Bowel & Cancer Research |
| Cochrane Upper Gastrointestinal and Pancreatic Diseases Group | |
| CORE (Digestive Disorders Foundation) | |
| Health Research Authority | |
| Institute of Cancer Research | |
| MRC Clinical Trials Unit | |
| National Cancer Research Institute | |
| National Cancer Research Network | |
| National Institute for Health Research | |
| Research Institute for the Care of Older People |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 July 2014 | We are suspending this appraisal. This is because the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has decided not to approve masitinib for treating unresectable or metastatic gastrointestinal stromal tumours after treatment with imatinib. |
| 20 February 2014 | Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance